```html

Kawasaki Disease – IVIG‑Resistant

Overview

Kawasaki disease (KD) is an acute, self‑limited vasculitis that primarily affects medium‑sized arteries, especially the coronary arteries. Most children recover with standard therapy, but a subset (≈10‑20 % of patients) do not respond to the first dose of intravenous immunoglobulin (IVIG) and are classified as **IVIG‑resistant**. This group has a higher risk of coronary artery aneurysms and requires more aggressive treatment.

**Who it affects** – KD is the leading cause of acquired heart disease in children in high‑income countries. It most commonly occurs in children <5 years old (median age 2–3 years), with a male‑to‑female ratio of about 1.5–1.6 : 1. The disease is most frequent in East Asian populations (Japan, Korea, Taiwan) where incidence can exceed 300 cases per 100,000 children under five, compared with 10–20 per 100,000 in the United States and Europe. IVIG resistance appears slightly more common in Asian children, but it occurs worldwide.

Symptoms

Kawasaki disease is diagnosed based on a set of clinical criteria. In IVIG‑resistant cases, the initial presentation is the same as classic KD, but the fever persists ≥48 hours after the first IVIG infusion.

Core diagnostic features (≥5 of 6)

• Fever: Persistent high fever (≥39 °C/102.2 °F) lasting at least 5 days.
• Conjunctival injection: Bilateral, non‑exudative “red eyes” without crusting.
• Oral changes: Cracked, “strawberry” tongue; red, fissured lips; diffuse erythema of the oropharynx.
• Extremity changes: Acute: erythema and edema of the hands/feet; subacute: periungual desquamation (peeling) beginning 2–3 weeks after onset.
• Rash: Polymorphous, non‑vesicular rash, often beginning on the trunk and spreading.
• Cervical lymphadenopathy: Typically unilateral, >1.5 cm in diameter, tender.

Additional findings that may appear

• Joint pain or arthritis (often transient)
• Gastrointestinal symptoms (vomiting, diarrhea, abdominal pain)
• Irritability or lethargy, especially in infants
• Hepatomegaly or mild liver enzyme elevation
• Gallbladder hydrops (fluid‑filled gallbladder)
• Menstrual irregularities in adolescent females (rare)

Causes and Risk Factors

The exact cause of Kawasaki disease remains unknown, but current research points to a multifactorial process:

• Infectious trigger: Seasonal peaks and clustering of cases suggest an infectious agent (viral or bacterial) that provokes an abnormal immune response in genetically susceptible children.
• Genetics: Polymorphisms in genes related to immune regulation (e.g., ITPKC, CASP3, FCGR2A) increase susceptibility and may influence IVIG resistance.
• Immune dysregulation: Over‑activation of T‑cells, cytokine storms (elevated TNF‑α, IL‑6, IL‑1β), and endothelial injury drive the vasculitis.

Risk factors for IVIG resistance

• Age < 1 year or > 10 years
• Male gender
• High baseline C‑reactive protein (CRP > 10 mg/dL) or neutrophil count
• Low albumin (< 3.0 g/dL) or hyponatremia
• Presence of coronary artery abnormalities at diagnosis
• Delayed treatment (> 10 days after fever onset)

Diagnosis

Diagnosis is clinical, supported by laboratory and imaging studies to assess inflammation and cardiac involvement.

Laboratory tests

• Complete blood count (CBC): elevated white blood cells with neutrophilia, anemia, thrombocytosis (platelets rise in subacute phase).
• Inflammatory markers: CRP and erythrocyte sedimentation rate (ESR) markedly increased.
• Liver panel: modest transaminase elevation.
• Serum albumin: often low.
• Urinalysis: sterile pyuria (white cells without bacteria) common.
• Ferritin, IL‑6, and other cytokines may be elevated in severe or IVIG‑resistant cases (research setting).

Cardiac imaging

• Echocardiogram: First‑line; evaluates coronary artery dimensions, detects aneurysms, assesses ventricular function.
• Cardiac MRI or CT angiography: Used when echocardiography is inconclusive or to further characterize large aneurysms.

Scoring systems for IVIG resistance

Several predictive scores (e.g., Kobayashi, Egami, Sano) combine laboratory and clinical variables to estimate the likelihood of IVIG resistance. While not perfect, they help clinicians decide early on whether adjunctive therapy may be needed.

Treatment Options

Prompt therapy reduces the risk of coronary complications. Standard treatment consists of a single high‑dose IVIG infusion and aspirin; IVIG‑resistant disease requires escalation.

First‑line therapy (for all KD patients)

• IVIG: 2 g/kg given as a single infusion over 10‑12 hours, ideally within the first 10 days of fever.
• Aspirin: High dose (30‑50 mg/kg/day divided q6h) until afebrile for 48 h, then low dose (3‑5 mg/kg/day) for antiplatelet effect, continued for 6‑8 weeks or longer if coronary changes persist.

Management of IVIG‑resistant KD

Resistance is defined as persistent or recrudescent fever ≥36 h after the end of the initial IVIG infusion.

1. Second dose of IVIG: 2 g/kg is commonly repeated.
2. Corticosteroids:
   • Intravenous methylprednisolone 30 mg/kg/day for 1–3 days, followed by oral prednisolone 2 mg/kg/day tapered over 2–3 weeks.
   • Evidence (e.g., RAISE trial, NEJM 2016) shows that adding steroids to initial therapy reduces coronary artery abnormalities, especially in high‑risk patients.
3. Infliximab (anti‑TNF‑α): Single dose 5 mg/kg IV; useful when both IVIG and steroids fail or are contraindicated. Randomized data (Kobayashi et al., 2020) show faster fever resolution.
4. Other biologics:
   • Etanercept (TNF‑α blocker) – limited data, used in refractory cases.
   • Anakinra (IL‑1 receptor antagonist) – emerging option, especially for patients with high IL‑1 levels or Kawasaki‑shock syndrome.
5. Plasma exchange: Considered in fulminant, refractory disease or when coronary aneurysms are rapidly expanding.

Adjunctive measures

• Continue low‑dose aspirin; add clopidogrel if giant aneurysms (> 8 mm) develop.
• Monitor fluid balance; avoid dehydration which can worsen coronary perfusion.
• In rare cases of Kawasaki‑shock syndrome, treat with aggressive fluid resuscitation and vasopressors in an intensive‑care setting.

Living with Kawasaki Disease – IVIG‑Resistant

Even after the acute illness resolves, families face ongoing concerns. The following tips help with day‑to‑day management and long‑term health.

Follow‑up schedule

• First 2 weeks: Repeat echocardiogram at 1–2 weeks post‑IVIG to assess coronary status.
• 6‑week mark: Second echo; if normal, low‑dose aspirin can often be stopped.
• 6 months and 1 year: Additional imaging for patients with persistent abnormalities.
• Cardiology referral for any detected aneurysm, regardless of size.

Medication adherence

• Use a pill organizer or set reminders for aspirin and any steroid taper.
• Discuss side‑effects (e.g., stomach upset from aspirin) with the pediatrician; antacids may be prescribed.

Activity recommendations

• Normal activity is generally safe once fever resolves and the child feels well.
• If coronary aneurysms are present, limit vigorous exertion (e.g., contact sports) until cleared by a cardiologist.

Nutrition & hydration

• Offer a balanced diet rich in fruits, vegetables, whole grains, and lean protein to support vascular healing.
• Encourage fluids (water, electrolyte solutions) especially during the first month, when fever and inflammation may increase fluid loss.

Emotional support

• Explain the disease in age‑appropriate language; reassure the child that most recover fully.
• Connect families with support groups (e.g., Kawasaki Disease Foundation) for shared experiences.

Prevention

Because the exact trigger is unknown, specific primary prevention is not possible. However, general measures can reduce the likelihood of severe disease or complications:

• Prompt medical evaluation for any child with > 5 days of high fever and at least two compatible clinical signs.
• Maintain routine pediatric well‑child visits; early detection of subtle signs (e.g., conjunctival redness) improves outcomes.
• Good hand hygiene and avoidance of sick contacts may lower exposure to potential infectious triggers.

Complications

If untreated or inadequately treated, Kawasaki disease can lead to serious, sometimes life‑threatening problems.

Cardiac complications (most common)

• Coronary artery aneurysms: Occur in 15‑25 % of untreated cases; risk rises to 5‑10 % in IVIG‑resistant patients.
• Myocarditis, pericarditis, and valvular regurgitation (rare).
• Ischemic heart disease or myocardial infarction in adolescence or adulthood due to thrombosis of aneurysmal vessels.

Non‑cardiac complications

• Medium‑vessel vasculitis affecting peripheral arteries → limb ischemia (very rare).
• Neurologic sequelae: irritability, aseptic meningitis, or, in Kawasaki‑shock syndrome, encephalopathy.
• Gastrointestinal: hydrops of the gallbladder, intestinal edema, or pancreatitis.

When to Seek Emergency Care

References

• Mayo Clinic. Kawasaki disease. https://www.mayoclinic.org/diseases‑conditions/kawasaki-disease/
• CDC. Kawasaki Disease. https://www.cdc.gov/kawasaki/
• Newburger JW, et al. "Management of Kawasaki Disease." NEJM. 2016;374:1874‑1882.
• Uehara R, et al. "Predictive Scores for IVIG Resistance." Cleveland Clinic Journal of Medicine. 2020.
• Japanese Society of Kawasaki Disease. Annual epidemiological report 2023.
• World Health Organization. Guidelines on childhood vasculitis. 2022.

```